Catabasis Pharmaceuticals, Inc. (CATB) financial statements (2020 and earlier)

Company profile

Business Address ONE KENDALL SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:4138163963
Cash and cash equivalents1815162463
Short-term investments2322 15 
Other undisclosed cash, cash equivalents, and short-term investments(0)0   
Other undisclosed current assets21111
Total current assets:4339174064
Noncurrent Assets
Property, plant and equipment 0011
Other noncurrent assets00  0
Other undisclosed noncurrent assets10000
Total noncurrent assets:10011
TOTAL ASSETS:4439184064
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54355
Accounts payable21111
Accrued liabilities23243
Debt  233
Other liabilities  0  
Other undisclosed current liabilities1    
Total current liabilities:64688
Noncurrent Liabilities
Liabilities, other than long-term debt 0000
Deferred revenue and credits000
Deferred rent credit 0
Other liabilities 0 00
Other undisclosed noncurrent liabilities   26
Total noncurrent liabilities: 0036
Total liabilities:6461114
Stockholders' equity
Stockholders' equity attributable to parent3835122950
Common stock00000
Additional paid in capital255232183173158
Accumulated other comprehensive loss (0) (0) 
Accumulated deficit(217)(197)(171)(144)(108)
Total stockholders' equity:3835122950
TOTAL LIABILITIES AND EQUITY:4439184064

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net0  
Gross profit:  1  
Operating expenses(26)(26)(28)(36)(32)
Operating loss:(26)(26)(27)(36)(32)
Nonoperating income (expense)11(0)(1)(1)
Investment income, nonoperating1000 
Other nonoperating income (expense)(0)0000
Interest and debt expense (0)(0)(1)(1)
Loss before gain (loss) on sale of properties:(26)(26)(28)(37)(34)
Other undisclosed net income 00  
Net loss:(26)(26)(27)(37)(34)
Other undisclosed net income attributable to parent   11
Net loss available to common stockholders, diluted:(26)(26)(27)(36)(33)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(26)(26)(27)(37)(34)
Comprehensive loss:(26)(26)(27)(37)(34)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)01 
Comprehensive loss, net of tax, attributable to parent:(26)(26)(27)(36)(34)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: